A Cascade Approach to Cyclic Aminonitrones: Reaction Discovery, Mechanism, and Scope-Reference-Cited by-同舟云学术

A Cascade Approach to Cyclic Aminonitrones: Reaction Discovery, Mechanism, and Scope

Published:2009-07-02 Issue:15 Volume:11 Page:3194-3197
ISSN:1523-7060
Container-title:Organic Letters
language:en
Short-container-title:Org. Lett.

Author:

Sharma Rojita¹,Bulger Paul G.¹,McNevin Michael¹,Dormer Peter G.¹,Ball Richard G.¹,Streckfuss Eric¹,Cuff James F.¹,Yin Jingjun¹,Chen Cheng-yi¹

Affiliation:

1. Departments of Process Research, Pharmaceutical Research and Development, and Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ol9010147

Reference44 articles.

1. Raltegravir was approved by the FDA in October 2007 for the treatment of HIV/AIDS and is marketed under the trademark Isentress.

2. Current Developments in HIV Chemotherapy

3. HIV Integrase, a Brief Overview from Chemistry to Therapeutics

4. Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells

5. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Strategic Synthesis of Fluoroethers via Ring-Opening Fluorinative Beckmann Fragmentation;Organic Letters;2023-08-24

2. VLSI Architecture Design Methodology for Deep learning based Upper Limb and Lower Limb Movement Classification for Rehabilitation Application;2022 IEEE 13th Latin America Symposium on Circuits and System (LASCAS);2022-03-01

3. An outstanding cyclocondensation of 2-aminopyrazine;Journal of Molecular Structure;2021-10

4. Two (Chemo)-Enzymatic Cascades for the Production of Opposite Enantiomers of Chiral Azidoalcohols;Catalysts;2021-08-17

5. Copper-catalyzed Beckmann-type fragmentation of less-strained cycloketoxime esters;Organic Chemistry Frontiers;2021